Results: Aβ+ aMCI individuals (relative to Aβ-) showed faster decline in paired associates learning (PAL) (p=0.02, ES=0.4) over 12 months. Aβ+ aMCI individuals who were APOE ɛ4 carriers (compared to non-carriers) had a greater decline in PAL (p<0.01, ES=0.6). No other cognitive domain including attention and executive function were affected by Aβ positivity and/or APOE ɛ4 carriage. Conclusions: Aβ+ individuals with aMCI declined at a faster rate over 12-months on episodic memory. The decline in memory in Aβ+ individuals with aMCI was exacerbated by the presence of the APOE ɛ4 allele. Other cognitive domains including psychomotor speed, attention and executive function were not affected Aβ positivity and/or APOE e4 carriage. These findings suggest a memory decline in Aβ+ individuals with aMCI can be detected as early as 12 months using the CANTAB PAL task of episodic memory.
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Placebo effects in Alzheimer Disease: analysis of the CATIE-AD data Abstract Background: Differences in symptom trajectories of behavioral and psychological symptoms with dementia (BPSD) between placebo and active drug responders have not been investigated. Additionally, ideal criteria for screening of potential placebo responders in a placebo lead-in phase in clinical trials for BPSD remain unknown. Methods: The data of 371 patients with Alzheimer disease (DSM-IV) in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness for Alzheimer disease (The CATIE-AD) were analyzed. The patients were randomly assigned to treatment with olanzapine, quetiapine, risperidone, or placebo in a double-blind condition. Trajectories of Brief Psychiatric Rating Scale (BPRS) total scores were compared between placebo and active drug responders (i.e. those who achieved a ≥25% BPRS total score reduction). Prediction performance of binary classification in improvement at week 2 for placebo response at week 8 was examined; sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the consecutive cut-off points in increments of 5% between 5% and 25% in the BPRS total score reduction at week 2 were calculated. Results: There were no significantly differences in symptom trajectories between placebo and drug groups. The cut-off of 10% at week 2 presented with the highest precision of 0.66 with sensitivity, NPV, specificity, and PPV of 0.53, 0.65, 0.77, and 0.68, respectively. Conclusion: Symptom trajectories of BPSD in responders follow a similar pattern irrespective of treatment modalities. The 10% cut-off at week 2 seems robust for the prediction of subsequent placebo response at week 8, which may need to be considered in future clinical trials to reduce failure trials for BPSD.
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Incidence and course of depression in Alzheimer's disease patients
Seung-Ho Ryu, Seung-Ho Ryu Konkuk University Medical Center, Republic of Korea
Abstract Objectives: Depressive symptoms are common in Alzheimer's Disease (AD). It is important to consider depressive symptoms not only as an aura of the disease but as symptoms that influence prognosis. Depression could appear anytime in the course of the disease, and could either last considerably long or disappear easily. This study intended to investigate the occurrence of depression in the course of AD and the risk factors of incidence. Method: This study targeted 1,272 AD patients without depressive symptoms at the start of this study in Korea. A total of 775 subjects completed the study, and the occurrence of depression was assessed after 12 months. Demographic information of subjects was collected and cognitive functions, overall functions, and depression severity were assessed at the start of this study and after 12 months. The average age of the subjects was 76.43 years, 67.22% of them were female, and years of education was 7.15 years. Results: Among the 775 subjects, 103 subjects (13.29%) developed depression 12 months later. The MMSE-KC scores showed significant changes in both groups that developed depression and did not (p=0.0448, p<0.0001). In the univariate analysis, significant differences in the incidence of depression were found in terms of gender (p=0.0108), the administration of the antidepressant at the baseline (p<0.0001), the SGDS-K score (p=0.0253), and the GDS (Global Deterioration Scale) score (p=0.0012). The multiple logistic regression analysis showed that the increase in the incidence of depression was associated with a female (p=0.0183), in the increase in SGDS-K score (p=0.0168) and the GDS score (p=0.0016).
Conclusion:
The incidence of depression in the subjects who completed the 12-month follow-up observation was 13.29%. Moreover, in the multivariate analysis, a female gender and the severity of dementia, including the overall functions, seemed associated with the occurrence of depression. Key words: Depression, Incidence, Course, Alzheimer's disease
PT596
The comparison with galantamine and donepezil on Alzheimer's Disease patients and its relationship with cerebral blood flow In this study, we compared the effect of galantamine and donepezil, by investigating the cognitive function, behavioral and psychological symptoms of dementia (BPSD) and the care burden, in patients with Alzheimer's disease (AD). Furthermore, with Near-Infrared Spectroscopy (NIRS), we examined the association between effect of galantamine and donepezil and brain blood flow. Methods: Evaluated the effect of galantamine and donepezil from baseline on Clinical Global Impression -Improvement scale (CGI-I), Mini-Mental State Examination (MMSE), Clock Drawing Test (CDT), Neuropsychiatric Inventory (NPI), Japanese version of the Zarit Burden Interview (J-ZBI) and NIRS in two groups, the donepezil group (n=14) and the galantamine group (n=13) were assessed at weeks 0, 4, 12, and 24.
